Get the Flash Player to see this video.

MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of cancer, autoimmune disorders and infectious diseases.  Learn More

  MacroGenics' Corporate Fact Sheet

Clinical Pipeline Highlights

View full chart
Program (Target) Indication Pre-
Clin.
Ph.
1
Ph.
2
Ph.
3
ONCOLOGY        
Margetuximab  (HER2) Breast (3+/FISH+) *  *  *  * 
MGA271  (B7-H3) Solid Tumors *  *  *  * 
MGD006  (CD123 x CD3) AML *  *  *  * 
MGD007  (gpA33 x CD3) Colorectal *  *  *  * 
AUTOIMMUNE        
Teplizumab  (CD3) T1D - At-Risk *  *  *  * 

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

Company Highlights

  • Emerging leader in developing therapeutics for immuno-oncology and autoimmune disorders
  • Fully-integrated mAb-based development capabilities, including proprietary technology platforms and protein engineering expertise
  • Differentiated pipeline directed against both novel and validated targets
  • Collaborations with Janssen, Takeda, Gilead, Servier, Boehringer Ingelheim and Pfizer
  • Experienced management team and highly collaborative corporate culture
Learn more

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Fierce Biotech 2013

MacroGenics was selected as a 2013 Fierce 15 by Fierce Biotech.  Learn more